Articles found by an AI-assisted PubMed search that may be missing from CancerImmunoDB, shared so that curators and users can see what is being considered.
Why this exists: the database holds only about 10 articles a year for 2021–2024, and a plain PubMed search cannot judge whether a paper fits the scope.
| Year | Screened | Likely relevant |
|---|---|---|
| 2026 | 99 | 61 |
| 2025 | 100 | 81 |
| 2024 | 98 | 72 |
| 2023 | 92 | 45 |
| 2022 | 100 | 52 |
| 2021 | 85 | 49 |
360 articles shown. “In the database” counts the entries the database already has for each drug the AI named (cell line / animal / patient).
| PMID | Year | Article | Drugs | Study type | Cancer type | In the database | Curator status |
|---|---|---|---|---|---|---|---|
| 37657247 | 2023 | Single-cell profiling reveals the heterogeneity of NK cells during anti-PD-1 therapy in non-small-cell lung cancer. International immunopharmacology Likely relevant The study experimentally analyzes single-cell transcriptome data from NSCLC patients treated with anti-PD-1 therapy, measuring immune cell subtypes and immune-related processes. | anti-PD-1 | Patient | non-small-cell lung cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 37731001 | 2023 | The β1-adrenergic receptor links sympathetic nerves to T cell exhaustion. Nature Likely relevant The study tests beta-blockers and immune checkpoint blockade in animal tumor models and evaluates effects on CD8+ T cell responses and exhaustion. | immune checkpoint blockade; beta-blockers | Animal | melanoma and pancreatic cancer | immune checkpoint blockade 0/1/0; beta-blockers 0/0/0 | Awaiting curator check |
| 37749092 | 2023 | THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer. Nature communications Likely relevant The study uses orthotopically generated CRC mouse models to evaluate the effect of THBS1 loss combined with immune checkpoint inhibitors and anti-cancer drugs on T-cell exhaustion and antitumor immunity. | immune checkpoint inhibitors; anti-cancer drugs | Animal | colorectal cancer | immune checkpoint inhibitors 0/0/0; anti-cancer drugs 0/0/0 | Awaiting curator check |
| 37752135 | 2023 | PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models. Nature communications Likely relevant The study experimentally tests a PARP14 inhibitor and anti-PD-1 therapy in mouse tumor models, measuring effector T cell and regulatory T cell infiltration. | alpha-PD-1; PARP14 inhibitor | Animal | melanoma and other syngeneic mouse tumor models | alpha-PD-1 0/0/0; PARP14 inhibitor 0/0/0 | Awaiting curator check |
| 37776054 | 2023 | Intratumoral administration of unconjugated Accum™ impairs the growth of pre-established solid lymphoma tumors. Cancer science Likely relevant Tests unconjugated Accum alone and with immune checkpoint inhibitors in cell lines and lymphoma-bearing animals, measuring ROS, immunogenic cell death, and T cell involvement. | Accum; anti-CTLA4; anti-PD-1; anti-CD47 | Mixed | lymphoma | Accum 0/0/0; anti-CTLA4 0/0/0; anti-PD-1 14/36/0; anti-CD47 0/0/0 | Awaiting curator check |
| 37777506 | 2023 | STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immunosuppression in acute myeloid leukemia. Signal transduction and targeted therapy Likely relevant The study investigates the effect of immune checkpoint inhibitors on reactive CD8+ T cells when co-cultured with AML cells exhibiting STAT5-induced glycolysis and PD-L1 expression. | immune checkpoint inhibitor; PD-1/PD-L1 blocker | Cell line | acute myeloid leukemia | immune checkpoint inhibitor 0/0/0; PD-1/PD-L1 blocker 0/0/0 | Awaiting curator check |
| 37794185 | 2023 | The PTPN2/PTPN1 inhibitor ABBV-CLS-484 unleashes potent anti-tumour immunity. Nature Likely relevant The study experimentally tests the PTPN2 and PTPN1 inhibitor ABBV-CLS-484 in vitro and in mouse models, measuring its effects on immune cell activation, NK and CD8+ T cell function, and the tumor microenvironment. | ABBV-CLS-484; PD-1 blockade | Mixed | advanced solid tumours | ABBV-CLS-484 0/0/0; PD-1 blockade 0/0/0 | Awaiting curator check |
| 37865045 | 2023 | The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors. EBioMedicine Likely relevant Tests immunotherapy combined with a microbial metabolite in mice and measures T cell and NK cell activation. | anti-CTLA-4; anti-PD-1 | Animal | cancer | anti-CTLA-4 1/10/7; anti-PD-1 14/36/0 | Awaiting curator check |
| 37880183 | 2023 | MCT4 blockade increases the efficacy of immune checkpoint blockade. Journal for immunotherapy of cancer Likely relevant The study tests MCT inhibitors and anti-PD-L1 in vitro and in vivo, and measures immune cell infiltration, T-cell function and activation. | AZD3965; MCT4 inhibitor; anti-PD-L1 | Mixed | colorectal carcinoma | AZD3965 0/0/0; MCT4 inhibitor 0/0/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 33692094 | 2022 | Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic cell-mediated antitumour immunity. Gut Likely relevant The study tests an anti-WNT2 monoclonal antibody and anti-PD-1 in mouse models and measures their effects on dendritic cell differentiation and antitumour T-cell responses. | anti-WNT2 monoclonal antibody; anti-programmed cell death protein 1 (PD-1) | Animal | oesophageal squamous cell carcinoma and colorectal cancer | anti-WNT2 monoclonal antibody 0/0/0; anti-programmed cell death protein 1 (PD-1) 0/0/0 | Awaiting curator check |
| 34160685 | 2022 | T-cell responses and combined immunotherapy against human carbonic anhydrase 9-expressing mouse renal cell carcinoma. Cancer immunology, immunotherapy : CII Likely relevant The study tests ICIs combined with cyclophosphamide or axitinib in mice and evaluates T-cell infiltration and responses. | anti-PD-1; anti-CTLA-4; cyclophosphamide; axitinib | Animal | renal cell carcinoma | anti-PD-1 14/36/0; anti-CTLA-4 1/10/7; cyclophosphamide 5/15/9; axitinib 5/7/0 | Awaiting curator check |
| 34253574 | 2022 | Helicobacter pylori infection has a detrimental impact on the efficacy of cancer immunotherapies. Gut Likely relevant The study investigates the impact of Helicobacter pylori infection on the efficacy and immune readouts of checkpoint inhibitors and cancer vaccines in mouse models and human cohorts. | anti-CTLA-4; anti-PD-L1; anti-PD-1 | Mixed | colon adenocarcinoma and melanoma | anti-CTLA-4 1/10/7; anti-PD-L1 0/15/0; anti-PD-1 14/36/0 | Awaiting curator check |
| 34278517 | 2022 | Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1/PD-L1 inhibitors. Cancer immunology, immunotherapy : CII Likely relevant The study evaluates lung cancer patients treated with PD-1/PD-L1 inhibitors and measures the effect on circulating regulatory T cells. | PD-1/PD-L1 inhibitors | Patient | lung cancer | PD-1/PD-L1 inhibitors 0/0/0 | Awaiting curator check |
| 34349241 | 2022 | Tumor suppressor immune gene therapy to reverse immunotherapy resistance. Cancer gene therapy Likely relevant The study experimentally tests gene therapy combined with immune checkpoint inhibitors and agonists in an animal tumor model and measures changes in gene expression profiles related to immune signatures. | adenoviral p53; anti-PD-1; IL2 or IL15 CD122/132 agonists | Animal | melanoma | adenoviral p53 0/0/0; anti-PD-1 14/36/0; IL2 or IL15 CD122/132 agonists 0/0/0 | Awaiting curator check |
| 34774916 | 2022 | The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma. Immunology letters Likely relevant The study tests an oncolytic virus combined with pembrolizumab in mice and measures immune cell infiltration, cytokine secretion, and PD-L1 expression. | VT09X; pembrolizumab | Animal | melanoma | VT09X 0/0/0; pembrolizumab 0/0/16 | Awaiting curator check |
| 34825915 | 2022 | WEE1 inhibition induces anti-tumor immunity by activating ERV and the dsRNA pathway. The Journal of experimental medicine Likely relevant The study tests a WEE1 inhibitor combined with PD-L1 blockade in tumor models, measuring ERV expression, dsRNA pathway activation, interferon response, and CD8+ T cell recruitment. | WEE1 inhibitor; PD-L1 blockade | Animal | tumor models | WEE1 inhibitor 0/0/0; PD-L1 blockade 0/4/0 | Awaiting curator check |
| 34898004 | 2022 | Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer. EMBO molecular medicine Likely relevant Tests Carfilzomib in high-throughput assays and a transgenic mouse model, measuring macrophage reprogramming, cytokine expression, and antigen presentation. | Carfilzomib; PD-1 antibody | Mixed | lung cancer | Carfilzomib 0/0/0; PD-1 antibody 0/3/0 | Awaiting curator check |
| 34981670 | 2022 | Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer communications (London, England) Likely relevant The study experimentally tests anti-PD-1 antibodies and the anti-PD-L1/TGF-betaR fusion protein SHR-1701 in lung cancer models and patients, measuring immune cell subsets and functions. | SHR-1701; anti-PD-1 antibodies | Mixed | lung cancer | SHR-1701 0/0/0; anti-PD-1 antibodies 0/0/0 | Awaiting curator check |
| 35122074 | 2022 | Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nature cancer Likely relevant The study experimentally tests trametinib and nintedanib in combination, and evaluates their effect on tumor microenvironment remodeling and T cell infiltration. | trametinib; nintedanib; anti-PD-L1 | Mixed | pancreatic ductal adenocarcinoma | trametinib 59/33/6; nintedanib 0/0/0; anti-PD-L1 0/15/0 | Awaiting curator check |
| 35132961 | 2022 | Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC. JCI insight Likely relevant Tests anti-PD-L1 and anti-CD73 antibodies in cell lines and xenograft mouse models, measuring T cell killing, proliferation, infiltration, and cytokine production. | anti-PD-L1; anti-CD73 | Mixed | non-small cell lung cancer | anti-PD-L1 0/15/0; anti-CD73 0/0/0 | Awaiting curator check |
| 35145222 | 2022 | Cancer-cell-derived GABA promotes β-catenin-mediated tumour growth and immunosuppression. Nature cell biology Likely relevant The study tests anti-PD-1 immune checkpoint blockade therapy in mouse models and evaluates its effects on CD8+ T cell intratumoural infiltration. | anti-PD-1 | Animal | cancer | anti-PD-1 14/36/0 | Awaiting curator check |
| 35236758 | 2022 | Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. Life science alliance Likely relevant The study tests immune checkpoint blockade therapy in mouse syngeneic tumor models and correlates Meflin-positive CAFs with CD4-positive T-cell infiltration. | immune checkpoint blockade | Animal | non-small cell lung cancer | immune checkpoint blockade 0/1/0 | Awaiting curator check |
| 35241835 | 2022 | The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response. Nature cancer Likely relevant The study investigates the role of Tht cells and their interaction with dendritic cells in harnessing the antitumor response of anti-PD-1 treatment using in vitro and mouse models. | anti-PD-1 | Mixed | non-small cell lung carcinoma | anti-PD-1 14/36/0 | Awaiting curator check |
| 35254416 | 2022 | Characterization of INCB086550: A Potent and Novel Small-Molecule PD-L1 Inhibitor. Cancer discovery Likely relevant The study experimentally tests a novel small-molecule PD-L1 inhibitor (INCB086550) in vitro, in humanized mice, and in patients, and measures its effects on immune cell cytokine production, T-cell activation, and gene signatures. | INCB086550 | Mixed | unspecified | INCB086550 0/0/0 | Awaiting curator check |
| 35278076 | 2022 | Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors. The oncologist Likely relevant The study experimentally tests interferon gamma treatment on NSCLC and thoracic fibroblast cell lines and measures CXCL9 and PD-L1 expression. | interferon gamma | Mixed | thoracic SMARCA4-deficient undifferentiated tumors, non-small cell lung cancer | interferon gamma 0/0/0 | Awaiting curator check |